Clinical and histological evaluation of 1% nadifloxacin cream in the treatment of acne vulgaris in Korean patients

International Journal of Dermatology

Volumn 50, Issue 3, 2011, Pages 350-357

  Jung, Jae Yoon ^a,b   Kwon, Hyuck Hoon ^a   Yeom, Kkot Bora ^a   Yoon, Mi Young ^b   Suh, Dae Hun ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 8; NADIFLOXACIN; TRANSFORMING GROWTH FACTOR BETA;

ACNE VULGARIS; ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; ERYTHEMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KOREA; MALE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; EMOLLIENTS; FACIAL DERMATOSES; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; PATIENT SATISFACTION; QUINOLIZINES; REPUBLIC OF KOREA; YOUNG ADULT;

EID: 79951938916     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04701.x     Document Type: Article

References (29)

1. Krautheim A, Gollnick HP. Acne: topical treatment. Clin Dermatol 2004; 22: 398-407.
2. Ko HC, Song M, Seo SH, et al. Prospective, open-label, comparative study of clindamycin 1%/benzoyl peroxide 5% gel with adapalene 0.1% gel in Asian acne patients: efficacy and tolerability. J Eur Acad Dermatol Venereol 2009; 23: 245-250.
3. Gollnick HP, Krautheim A. Topical treatment in acne: current status and future aspects. Dermatology 2003; 206: 29-36.
4. Thiboutot D, Zaenglein A, Weiss J, et al. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol 2008; 59: 792-800.
5. Gollnick HP, Draelos Z, Glenn MJ, et al. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol 2009; 161: 1180-1189.
6. Dreno B. Topical antibacterial therapy for acne vulgaris. Drugs 2004; 64: 2389-2399.
7. Nenoff P, Haustein UF, Hittel N. Activity of nadifloxacin (OPC-7251) and seven other antimicrobial agents against aerobic and anaerobic Gram-positive bacteria isolated from bacterial skin infections. Chemotherapy 2004; 50: 196-201.
8. Kurokawa I, Akamatsu H, Nishijima S, et al. Clinical and bacteriologic evaluation of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base. J Am Acad Dermatol 1991; 25: 674-681.
9. Plewig G, Holland KT, Nenoff P. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: a double-blind, phase III comparison study versus erythromycin 2% cream. Eur J Dermatol 2006; 16: 48-55.
10. O'Brien SC, Lewis JB, Cunliffe WJ. The Leeds revised acne grading system. J Dermatolog Treat 1998; 9: 215-220.
11. Iwahara K, Ishii K, Chen Y, et al. Tufted hair folliculitis: response to topical therapy with nadifloxacin. Eur J Dermatol 1999; 9: 276-277.
12. Nishijima S, Nakagawa M, Tsuboi N, et al. Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: comparative study with seven other fluoroquinolones. J Int Med Res 1996; 24: 12-16.
13. Vogt K, Hermann J, Blume U, et al. Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris. Eur J Clin Microbiol Infect Dis 1992; 11: 943-945.
14. Kimata H. Effect of nadifloxacin on atopic dermatitis with methicillin-resistant Staphylococcus aureus in young children. Eur J Pediatr 1999; 158: 949.
15. Kuwahara K, Kitazawa T, Kitagaki H, et al. Nadifloxacin, an anti-acne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes. J Dermatol Sci 2005; 38: 47-55.
16. Allan GF, Sui Z. Therapeutic androgen receptor ligands. Nucl Recept Signal 2003; 1: e009.
17. Inui S, Nakao T, Itami S. Modulation of androgen receptor transcriptional activity by anti-acne reagents. J Dermatol Sci 2004; 36: 97-101.
18. Schachner L, Pestana A, Kittles C. A clinical trial comparing the safety and efficacy of a topical erythromycin-zinc formulation with a topical clindamycin formulation. J Am Acad Dermatol 1990; 22: 489-495.
19. Zouboulis CC, Derumeaux L, Decroix J, et al. A multicenter, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulgaris. Br J Dermatol 2000; 143: 498-505.
20. Alexis AF. Clinical considerations on the use of concomitant therapy in the treatment of acne. J Dermatolog Treat 2008; 19: 199-209.
21. Tirado-Sanchez A, Ponce-Olivera RM. Efficacy and tolerance of superoxidized solution in the treatment of mild to moderate inflammatory acne. A double-blinded, placebo-controlled, parallel-group, randomized, clinical trial. J Dermatolog Treat 2009; 20: 289-292.
22. Aramaki J, Kawana S, Effendy I, et al. Differences of skin irritation between Japanese and European women. Br J Dermatol 2002; 146: 1052-1056.
23. Robinson MK. Population differences in acute skin irritation responses. Race, sex, age, sensitive skin and repeat subject comparisons. Contact Dermatitis 2002; 46: 86-93.
24. Taylor SC, Cook-Bolden F, Rahman Z, et al. Acne vulgaris in skin of color. J Am Acad Dermatol 2002; 46(Suppl): 98-106.
25. Nam TJ, Moon KC, Kim JM, et al. Clinical effects of benzoyl peroxide on acne vulgaris. Korean J Dermatol 1978; 16: 459-463.
26. Jung JY, Choi YS, Yoon MY, et al. Comparison of a pulsed dye laser and a combined 585/1064-nm laser in the treatment of acne vulgaris. Dermatol Surg 2009; 35: 1181-1187.
27. Abd El All HS, Shoukry NS, El Maged RA, et al. Immunohistochemical expression of interleukin 8 in skin biopsies from patients with inflammatory acne vulgaris. Diagn Pathol 2007; 2: 4.
28. Ling E, Robinson DS. Transforming growth factor-β1: its anti-inflammatory and pro-fibrotic effects. Clin Exp Allergy 2002; 32: 175-178.
29. Kawamoto T, Tayama Y, Sawa A, et al. Effect of the admixture of tetracycline and nadifloxacin ointments on their stability and their antibacterial activity. Yakugaku Zasshi 2008; 128: 1221-1226.